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Abstract: Matrix metalloproteinases (MMPs) have traditionally been considered as tumor promoting
enzymes as they degrade extracellular matrix components, thus increasing the invasion of cancer
cells. It has become evident, however, that MMPs can also cleave and alter the function of various
non-matrix bioactive molecules, leading to both tumor promoting and suppressive effects. We
applied systematic review guidelines to study MMP8 in cancer including the use of MMP8 as a
prognostic factor or as a target/anti-target in cancer treatment, and its molecular mechanisms. A
total of 171 articles met the inclusion criteria. The collective evidence reveals that in breast, skin and
oral tongue cancer, MMP8 inhibits cancer cell invasion and proliferation, and protects patients from
metastasis via cleavage of non-structural substrates. Conversely, in liver and gastric cancers, high
levels of MMP8 worsen the prognosis. Expression and genetic alterations of MMP8 can be used as
a prognostic factor by examination of the tumor and serum/plasma. We conclude, that MMP8 has
differing effects on cancers depending on their tissue of origin. The use of MMP8 as a prognostic
factor alone, or with other factors, seems to have potential. The molecular mechanisms of MMP8 in
cancer further emphasize its role as an important regulator of bioactive molecules.
Keywords: matrix metalloproteinase 8; cancer; prognosis; molecular mechanism; cancer drug therapy;
systematic review
1. Introduction
The number of new cancer cases is expected to grow in the future as the lifetime risk of developing
cancer rises with increasing aging of the population [1]. Survival has increased in many cancers [2]
due to improvements in prevention [3], detection [4], diagnosis and treatment [5]. These advances
have been facilitated by extensive basic and clinical research utilizing in vitro methods, genetic
analysis and cell culture methods, as well as in vivo animal studies and clinical trials. Moreover, the
identification of an increasing number of cancer biomarkers has improved cancer diagnostics and
care [6]. Biomarkers, such as DNA, RNA, proteins, peptides or chemical modifications of biomolecules,
are used to assess the risk of developing a specific cancer, and to measure treatment responses and
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cancer progression [7]. Historically, biomarkers have been explored in blood, urine and tumors using
immunoassays and immunohistochemistry.
Members of the matrix metalloproteinase (MMP) family of zinc-dependent proteinases have been
proposed as biomarkers and therapeutic targets for various cancers [8]. These proteinases have been
mostly considered tumor-promoting because of their indisputable role in one of the hallmarks of cancer
progression—the degradation of the extracellular matrix (ECM) that correlates with cancer cell invasion
and metastasis [9]. MMP8, also known as neutrophil collagenase or collagenase-2, cleaves triple helical
type I collagen and numerous other ECM and non-ECM substrates [10]. MMP8 is released from
polymorphonuclear neutrophils (PMN) and hence plays an important part in mediating inflammation.
For example, expression of MMP8 is increased in gingivitis as well as periodontitis [11] and MMP8 has
been shown to suppress neuroinflammation [12] and inflammation in osteoarthritis [13]. Although
mostly released from neutrophils, MMP8 is also expressed by various other cells [14]. However, the
functions of MMP8 seem to be highly diverse, and thus, no clear consensus for its role in cancer has
been reached. Moreover, its molecular mechanisms in different cancer types are still largely unknown.
The previous review articles on the role of MMP8 in cancer are outdated, do not focus solely on
MMP8 and are not systematic reviews on the subject [15,16]. By applying systematic review guidelines
and methods, we gathered the original research articles published on MMP8 related to cancer and
provide a comprehensive compilation of the current knowledge on the subject. We aim to create an
overview of the potential prognostic value of MMP8 in blood and tumor samples as well as highlight
the effect of genetic changes in MMP8 for prognosis. In vitro and in vivo (murine) studies are reviewed
to emphasize the molecular mechanisms of MMP8 and finally, the use of MMP8 in all levels of cancer
therapy is discussed.
2. Results
2.1. The Potential Use of MMP8 for Evaluating Cancer Prognosis
Prognosis refers to the likely course, duration and outcome of a disease based on its characteristics,
such as tumor size in cancer. The statistically calculated terms of overall survival (OS), disease-free
survival (DFS) and recurrence-free survival (RFS) are often used to describe the prognosis of a patient.
The Dictionary of the National Cancer Institute defines these terms as the average time from the start
of treatment to when the patient is still alive (OS), or the time from the end of treatment for which the
patient survives without any signs or symptoms of that cancer (DFS, sometimes referred as recurrence-
or relapse-free survival, RFS). Prognostic biomarkers are biomolecules, such as DNA or protein, which
inform the clinician of the patient’s status or enable them to predict the patient’s prospects, e.g., chance
of recurrence [7]. Here we evaluated the measurement of MMP8 (gene expression and protein levels)
in tumors and circulation, as well as genetic polymorphisms, as a prognostic marker.
2.1.1. Analysis of Tumoral MMP8 on Protein and mRNA Level
Levels of different molecules have been traditionally studied by visualizing target antigens using
immunohistochemical methods on fresh frozen or formalin-fixed, paraffin-embedded (FFPE) tumor
samples [17]. Tumor lysates can also be used as a source of protein for analysis [18]. Sometimes the
tumor samples are collected as microarrays (tumor microarray, TMA) [19]. Tumoral mRNA expression
has been usually studied by reverse transcriptase-polymerase chain reaction (RT-PCR) using RNA
extracted from fresh or FFPE tumor tissue [20]. Yet mRNA can also be visualized in tumor sections by
other methods such as in situ hybridization [21]. The studies on tumoral MMP8, both mRNA and
protein, are collected in Table 1.
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Table 1. Tumoral matrix metalloproteinase 8 expression and prognosis.
Cancer Focus Method Study Size (Patients +Healthy Controls) Expression and Prognosis (p-Value) Authors
Bladder mRNA RT-PCR 113 + 20 Positively correlates with tumor grade (p < 0.001). Wallard et al. 2006 [22]
Bone Protein IHC 25 + 0 5/10 resection samples and 11/22 biopsies but 0/3 metastases showMMP8 staining. Korpi et al. 2011 [23]
mRNA RT-PCR 29 + 0 5/29 chondrosarcoma tumors show expression. Scully et al. 1999 [24]
Breast mRNA RT-PCR 39 + 16 Trend to positive correlation with tumor grade (ns). Benson et al. 2013 [25]
Protein, mRNA RT-PCR, WB, IHC 20 + 5 No difference in mRNA. Protein correlates with stage (p ≤ 0.05). Köhrmann et al. 2009 [26]
Protein, mRNA IHC, RT-PCR 280 IHC, 250 RT-PCR + 10
mRNA expression negatively correlates with LN involvement
(p = 0.006). Better survival of patients without adjuvant therapy
(p = 0.009).
Gutierrez-Fernandez et al. 2008 [27]
mRNA Microarray 295 + 0 No correlation to clinicopathological features. McGowan & Duffy 2008 [28]
Luminal A; mRNA RT-PCR 25 + 0 No correlation to clinicopathological features. Decock et al. 2007 [29]
Protein ELISA 55 + 0 No correlation to tumor size or LN metastasis. Duffy et al. 1995 [30]
Colorectal Protein IHC 548 + 0 No correlation with clinicopathological features or prognosis. Koskensalo et al. 2012 [31]
Protein IHC 5 + 0 Very little staining (0.1–5%) in cancer cells. Väyrynen et al. 2012 [32]
Protein ELISA 100 + 0 Correlation with malignancy (p = NR). Verspaget et al. 1999 [33]
Protein IHC 121 + 0 No expression in cancer cells. Takeha et al. 1997 [34]
Gastric Protein IHC 276 + 0
Negative staining associates with stage I cancer (p = 0.022), T1 tumor
(p = 0.005), diffuse type (p < 0.001), no LN metastasis (p = 0.016) and
age under 67 (p = 0.007). Better prognosis for women with negative
staining (p = 0.026).
Laitinen et al. 2018 [35]
mRNA RT-PCR 34 + 34 Lower mRNA expression in cancer tissue compared to pairedhealthy tissue. Lin et al. 2017 [36]
mRNA RT-PCR 17 + 22 No difference between patients and controls and no correlation toclinicopathological features. de la Pena et al. 2014 [37]
Protein ELISA 81 + 0 Expression higher (p ≤ 0.001) esp. in well-differentiated (p ≤ 0.002)tumors. No correlation to survival. Kubben et al. 2006 [38]
Head and neck OTSCC; protein IHC 57 + 0
High VEGF-C (p = 0.001) and low MMP8 level (p = 0.01) correlate with
shorter CSS, combined VEGF-C+/MMP8- status correlate with poor
CSS (p < 0.001). No correlation to clinicopathological variables.
Åström et al. 2017 [39]
OSCC, CSCC; protein IHC 36 OSCC, 25 CSCC + 0 No correlation to clinicopathological features or overall survival. Ahmed Haji Omar et al. 2015 [40]
OSCC; protein IHC 25 + 0 5/25 tumors showed moderate levels. Lawal et al. 2015 [41]
OTSCC: protein IHC 70 + 0 No correlation to clinicopathological features. Mäkinen et al. 2012 [42]
Larynx; protein AG array 7 + 5 Levels higher compared to normal mucosa (p = NR). Korampalli et al. 2011 [43]
OTSCC; protein IHC 90 + 0 Correlation to better prognosis and lower-case fatality (p < 0.05). Korpi et al. 2008 [44]
SL, SCC; protein,
mRNA IHC, RT-PCR 32 + 32 <20% tumors showed expression (mRNA/protein). Xie et al. 2004 [45]
SG; protein EIA 23 + 23 No differences to normal tissue. Kayano et al. 2004 [46]
SCC; protein, mRNA IHC, ISH 19 + 0 Low mRNA expression and protein levels in all samples. Moilanen et al. 2002 [47]
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Table 1. Cont.
Cancer Focus Method Study Size (Patients +Healthy Controls) Expression and Prognosis (p-Value) Authors
Liver Protein IHC 73 + 0
Co-overexpression with TGF-β1 predicts poor prognosis in HCC
patients (p < 0.025). Correlation to cancer stage (p = 0.038) and
metastasis (p = 0.049).
Qin et al. 2016 [48]
Lung Protein FACS 22 SCC, 19 AC + 0 Higher in tumor (p = 0.0084) and SCC vs AC (p = 0.0023). Trendtowards positive correlation with recurrence (ns). Shah et al. 2010 [49]
Ovarian Protein IHC 302 + 0 Correlation to tumor stage (p ≤ 0.01), grade (p ≤ 0.01) and poorprognosis (p = 0.019). Stadlmann et al. 2003 [50]
Protein NR NR High MMP8 levels in ovarian cyst fluid are associated with malignancy(p = NR). Stenman et al. 2003 [51]
Pancreas Protein LC-MS 9 SS, 10 LS + 0 MMP8 upregulated in SS group (p < 0.05). Hu et al. 2018 [52]
Protein, mRNA IHC, RT-PCR 45 + 10
Expression higher (p = 0.04) in tumor versus healthy tissue.
No correlation to clinicopathological features or survival.
No mRNA found.
Jones et al. 2004 [53]
Skin nBCC; protein, mRNA RT-PCR, WB 22 + 22 Higher levels in nBCC tumors (p < 0.0001), but no differences inmRNA expression. Cia˛z˙yn´ska et al. 2018 [54]
SCC; protein IHC 31 KA, 15 SCC + 0 More frequent levels in keratoacanthomas compared to SCCs (ns) Kuivanen et al. 2006 [55]
SCC; protein IHC 9 SCC, 31 leg ulcers + 0 Cannot distinguish between non-malignant leg ulcers and SCC. Impola et al. 2005 [56]
Melanoma; protein IHC 10 + 0 Correlates with invasiveness (p = NR). Giambernardi et al. 2001 [57]
BCC; protein IHC 54 +16 No correlation to collagenolytic activity. Varani et al. 2000 [58]
Soft tissue Protein ICC 39 + 0 6/39 tumors have MMP8 staining. Roebuck et al. 2005 [59]
Thyroid mRNA cDNA array 131 + 0 Higher expression in malignant neoplasms compared to benign. Kebebew et al. 2005 [60]
Uterine Protein EIA, IHC 53 + 30 Higher expression (p < 0.05) in patients. No correlation toclinicopathological features. Ueno et al. 1999 [61]
Abbreviations: AC: Adenocarcinoma; AG array: Angiogenesis array; BCC: Basal cell carcinoma; CSCC: Cutaneous squamous cell carcinoma; CSS: Cancer specific survival; EIA: Enzyme
immunoassay; ELISA: Enzyme-linked immunosorbent assay; FACS: Fluorescence activated cell sorting/flow cytometry; HCC: Hepatocellular carcinoma; ICC: Immunocytochemistry; IHC:
Immunohistochemistry; ISH: In situ hybridization; LC-MS: Liquid chromatography—mass spectrometry; KA: Keratoacanthoma; LN: Lymph node; LS: Long survival; NR: Not reported;
nBCC: Nodular basal cell carcinoma; ns: Not significant; OSCC: Oral squamous cell carcinoma; OTSCC: Oral tongue squamous cell carcinoma; RT-PCR: Real-time or reverse transcription
polymerase chain reaction; SCC: Squamous cell carcinoma; SG: Salivary gland; SL: Supraglottic larynx; SS: Short survival; TGF-β1: Transforming growth factor β1; T1 tumor: Tumor
extending to mucosal and submucosal layers according to tumor, node, metastasis (TNM) staging for gastric cancer; VEGF-C: vascular endothelial growth factor C; WB: Western blot.
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2.1.1.1. No Clear Evidence for the Use of MMP8 Protein as a Prognostic Factor in Breast Cancer
MMP8 has been widely studied in breast tumors. Many studies have found no correlation
between tumoral MMP8 expression and clinicopathological parameters [25,28,29]. Köhrmann et al. [26]
detected a correlation between tumor grade and MMP8 protein levels, yet Sarper et al. [62] noticed a
loss of MMP8 in myoepithelial cells during carcinogenesis. Gutierrez-Fernandez et al. [27] showed
that MMP8 gene expression negatively correlated with lymph node involvement, but so far no other
study has confirmed the correlation. Another study on breast cancer showed an association between
MMP8 levels and the levels of metalloproteinase inhibitor 1 (TIMP-1) and MMP9 but not with tissue
plasminogen activator, urokinase or their inhibitor (PAI-1) [30,63].
2.1.1.2. The Prognostic Value of Tumoral MMP8 Protein Levels in Skin Cancer Depends on the Subtype
A higher level of MMP8 in the epidermal-dermal border correlates with melanoma invasiveness [57].
However, in basal cell carcinoma, MMP8 protein was only detected in the dermis and no correlation to
collagenolytic activity was observed [58]. Similarly, in squamous cell carcinoma (SCC) of the skin, the
epithelial level of MMP8 was not useful in distinguishing chronic, non-malignant leg ulcers from SCC [56],
nor to explain the aggressiveness of SCC in organ transplant recipients [64]. However, MMP8 was slightly
more frequently detected in neutrophils in keratoacanthomas (~44%) compared to SCCs (~33%) [55].
2.1.1.3. Tumoral MMP8 Protein Level is an Applicable Biomarker Only in Tongue SCC among All
Head and Neck SCCs
Analysis of MMP8, performed in a variety of different head and neck SCCs (HNSCCs), localized
MMP8 protein to tumor cell islands, PMNs, plasma cells and fibroblasts [47]. MMP8 is abundant in oral
squamous cell carcinoma (OSCC) tumors, but the higher level does not correlate with clinicopathological
features nor does it increase the survival of the patients [40,41]. Additionally, MMP8 was shown to be
present in the OSCC tumor interstitial fluid in samples collected during surgery and analyzed by mass
spectrometry [65]. Yet in the SCC of oral (mobile) tongue (OTSCC), higher MMP8 in tumor favored
better prognosis and lower mortality [44] although very high and negative levels hinted towards
shorter DFS [42]. Furthermore, high vascular endothelial growth factor C (VEGF-C) together with
low MMP8 levels in OTSCC tumors predicted worse prognosis even better than either of these factors
separately [39]. Patients with tonsillar SCC showed higher MMP8 levels compared to patients with
benign tonsillar disease [66]. MMP8 protein did not have a prognostic value in larynx tumors [43]
where its levels varied greatly between patients, nor in supraglottic laryngeal tumors [45] where it
was detected in only a few cells. Likewise, no difference in MMP8 protein levels were found between
salivary gland carcinomas and normal tissue [46].
2.1.1.4. Tumoral MMP8 Protein Level Associated with Malignancy in Ovarian and Liver Cancer and
Variates in Colorectal and Gastric Cancer
Qin et al. [48] found that MMP8 levels positively correlated with transforming growth factor β1
(TGF-β1) levels in hepatocellular carcinoma samples and their reciprocal increase was correlated with
cancer stage, metastasis and shorter time-to-recurrence. High cytoplasmic levels of MMP8 in ovarian
cancer cells correlated to tumor stage and overall poor prognosis, although not strongly enough to be
useful as a prognostic marker [50]. In the fluid of ovarian cysts, elevated levels of MMP8 was associated
with tumor malignancy [51]. It can be concluded, that high MMP8 seems to have a tumor-predicting
role in both liver and ovarian cancers. In colorectal cancer, correlation between the step-wise increase of
MMP8 levels and tumor malignancy was found [33]. Yet, others [31,34] did not find such a correlation
and Väyrynen et al. found the MMP8 protein mostly in necrotic areas and neutrophils [32]. Similarly
for gastric cancer, MMP8 level was higher in well-differentiated tumors, yet it did not affect patient
survival [38]. In contrast, Laitinen et al. [35] found that negative MMP8 staining was associated with
stage I cancer, T1 tumor stage as well as no lymph node metastasis and furthermore, women with
negative MMP8 staining had a better prognosis.
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For the following cancers, only single studies on the role of MMP8 exist. In the case of lung
cancers, MMP8 level, and possibly also its effect, depend on the cancer subtype [49]. Pancreatic
adenocarcinomas showed higher MMP8 levels compared to normal tissue [53], especially in patients
with short survival time [52]. In uterine cancer, MMP8 was more abundant in tumor samples compared
to normal tissue, but its level was not linked to any clinicopathological features such as tumor grade [61].
In chondrosarcoma [24] and soft tissue neoplasms [59], MMP8 staining was either absent or weak,
and thus, no conclusions could be made of its role. In jaw cysts, MMP8 was only detected in plasma
cells [67], and in osteosarcoma it was detected in about 50% of biopsy and resection samples but not at
all in metastases [23].
2.1.1.5. MMP8 mRNA Expression is Rarely Detected in Patient Samples
The expression of MMP8 mRNA has been detected only in a few chondrosarcomas [24],
hepatocellular carcinoma [68] and gastric cancer samples [37]. In bladder tumors, MMP8 mRNA
expression was not strong enough to show significant correlation to malignancy [22]. MMP8 mRNA
was elevated in skin samples of basal cell carcinoma patients compared to healthy controls [54] and in
malignant thyroid neoplasms compared to benign neoplasms [60]. Similarly, Merkerova et al. [69] and
Bruchova et al. [70] both noticed an up-regulation of MMP8 gene expression in the blood leukocytes
of chronic myeloid leukemia patients compared to healthy controls. Additionally, they showed that
MMP8 expression was not connected to hydroxyurea treatment and it can be effectively silenced
in vitro, but the effects of this expression were not discussed. On the other hand, MMP8 mRNA
expression was lower in gastric adenocarcinoma tumors compared to paired healthy tissue [36]. It could
be that MMP8 mRNA is not stable or that the protein expression detected in tumors does not originate
from cancer cells. The effects of tumoral MMP8 on cancer prognosis are illustrated in Figure 1 along
with the studies on MMP8 in blood.
Figure 1. The effect of MMP8 in tumor or blood on cancer prognosis. The size of the ball is in portion to
the number of publications on that cancer, the number in brackets depicts studies on mRNA or protein.
The color of the ball depicts the effects of MMP8 on that cancer.
2.1.2. MMP8 Levels in the Serum or Plasma
The circulatory system refers to the organ systems that circulate blood and lymph throughout
the body—both great sources of disease biomarkers. The studies on MMP8 in the circulation of
cancer patients have predominantly investigated MMP8 in blood, specifically in plasma and serum.
Linkov et al. [71] revealed that MMP8 levels in serum are unique to each individual, but they are also
stable, indicating that especially if the baseline level of the patient was known, MMP8 could be used as
a prognostic marker. No similar studies have been performed on plasma samples. Table 2 collates the
studies on circulatory MMP8 in various cancers.
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Table 2. Expression of matrix metalloproteinase 8 in blood and prognosis.
Cancer. Plasma/Serum Method Study Size (Patients +Healthy Controls) Expression and Prognosis Authors
Breast Serum Microarray 11 + 10 Higher in patients (p = 0.001). Li et al. 2017 [72]
Plasma ELISA 208 + 42
Higher in patients with non-inflammatory breast cancer (p = 0.007). Associated with
premenopausal status (p = 0.06), NPI (p = 0.04) and lymph node involvement (pN1-2
p = 0.001). Lower levels in patients with risk of distant metastasis (pN3, p = 0.003).
Decock et al. 2008 [73]
Colorectal Serum IFMA 335 + 47
Higher in patients with advanced disease (Dukes classification p < 0.001, T status p = 0.004),
distant metastasis (p < 0.001), tumor in right side of colon (p = 0.038). Correlation to worse
overall survival (p = 0.005)
Böckelman et al. 2018 [74]
Serum IFMA 271 + 0
Higher is patients with high mGPS (p < 0.001). Negative correlation with tumor-infiltrating
mast cells in invasive margin (p = 0.005) and tumor centre (p = 0.010). Correlation with poor
cancer-specific survival (p = 0.009).
Sirniö et al. 2018 [75]
Serum IFMA 116 + 83
Higher in patients (p = 0.0000000015). Correlation with TNM stage (p = 0.00045), T status
(p = 0.0035), distant metastasis (p = 0.000054), CLR (p = 0.0057), necrosis (p = 0.0024), high
neutrophil and leukocyte cell count (p < 0.05) and peritumoral tumor-destructing
inflammatory cell infiltrate (p = 0.041).
Väyrynen et al. 2012 [32]
Esophagus Serum Microarray 10 + 10 Lower expression in patients (p < 0.01). Tong et al. 2018 [76]
Gastric Serum IFMA 233 + 0 Higher expression in patients with intestinal cancer (p = 0.044). Patients with intermediate(31–131 ng/mL) serum MMP8 levels had better prognosis (p = 0.002). Laitinen et al. 2018 [35]
Head and neck Serum IFMA 33 SCC, 175 benign + 0 Higher in tonsillar SCC patients compared to patients with benign tonsillar disease (p = NR). Ilmarinen et al. 2017 [66]
Plasma IFMA 198 + 0 Trend towards favorable outcome (ns.). Nurmenniemi et al. 2012 [77]
Plasma IFMA 136 + 0 Does not correlate with survival or lymph node involvement. Pradhan-Palikhe et al. 2010[78]
Serum EIA 59 + 0 Higher than healthy persons (p < 0.05). Correlation with tumor stage (p = NR). Kuropkat et al. 2004 [79]
Serum NR 73 + 74 Higher than healthy persons, correlation with overall TNM status (p = NR). Kuropkat et al. 2002 [80]
Kidney Serum ELISA 43+ 10 Surgery lowers MMP-8 levels (p = NR). Kołomecki et al. 2001 [81]
Liver Serum IFMA 134 + 0 Worse overall survival (p = 0.013). Correlation to BCLC criteria (p < 0.0001) and tumor size(p < 0.0001). Lempinen et al. 2013 [82]
Melanoma Serum IFMA 117 + 0 Elevated in vascular-invading (p = 0.001), ulcerating (p = 0.003) and bleeding (p = 0.033)melanomas. Correlation to worse outcome (p = 0.023). Vihinen et al. 2008 [83]
Nerves Plasma NR 14 + 0 Elevated in carotid body cancer patients (p = NR). Serra et al. 2014 [84]
Pancreas Serum MAP kit 109 + 40 Expression higher in cancer patients (p = 0.0001). Park et al. 2012 [85]
Thyroid Plasma ELISA 22 + 0 No correlation with tumor presence (p = NR). Komorowski et al. 2002 [86]
Urothelial Plasma FACS 135 + 0 No correlation to clinical stage or cancer specific mortality in high-grade tumors. Svatek et al. 2010 [87]
Abbreviations: BCLC: Barcelona clinic liver cancer criteria; CLR: Crohn’s like lymphoid reaction; FACS: Fluorescence-activated cell sorter; (Fluorokine) MAP kit: Human MultiAnalyte
Profiling Base kit, R&D Systems; IFMA: Immunofluorometric assay; IFN-α: Interferon-α therapy; LN: Lymph node; mGPS: Modified Glasgow prognostic score; NPI: Nottingham
prognostic index; NR: Not reported; ns.: not significant; TNM: Tumor, node, metastasis staging.
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2.1.2.1. MMP8 Levels Increase with Malignancy in HNSCC Patients
Kuropkat et al. [79,80] found higher MMP8 levels in the serum of HNSCC patients compared to
healthy patients and MMP8 levels correlated with the T- and N-status and overall TNM stage (TNM
classification of malignant tumors, Union for International Cancer Control’s[UICC]). Plasma MMP8
levels did not correlate with survival or lymph node involvement [78]. Further analysis showed that
high MMP8 levels in plasma correlated with tumor stage IV and showed a trend (statistically not
significant) towards favorable outcomes [77].
2.1.2.2. High Serum MMP8 Level in Digestive System Cancers Predict Worse Prognosis
High serum MMP8 levels seem to hinder the survival of patients with various cancers of the
digestive and urinary systems. In colorectal cancer patients, increased serum MMP8 levels were
measured compared to healthy controls and a high MMP8 level correlated with malignancy, reduced
survival and increased systemic inflammation [32,74,75]. Moreover, in hepatocellular carcinoma, low
serum MMP8 levels correlated with better overall survival [82]. In pancreatic and kidney cancer
patients, serum MMP8 levels were increased compared to healthy controls but no correlation to any
clinicopathological features was found [81,85]. Interestingly, low or high MMP8 serum levels correlated
with poor prognosis in gastric cancer patients [35]. In regard to esophageal cancer, MMP8 levels were
significantly lower in serum samples from early stage patients compared to healthy controls [76].
MMP8 levels in plasma showed no correlation to clinical stage or cancer-related mortality in bladder
cancer patients [87].
2.1.2.3. The Prognostic Value of Circulating MMP8 Levels in Other Cancers Requires More Studies
In breast cancer patients, serum MMP8 levels were higher compared to healthy controls [72]. MMP8
expression in plasma was higher in patients with non-inflammatory breast cancer as well as in patients
with lymph node involvement, but interestingly, lower in patients with risk of distant metastasis [73].
Similarly, higher plasma MMP8 levels were demonstrated in carotid body paraganglioma patients
compared to healthy persons, but not patients with malignant disease [84]. Low serum MMP8 levels in
melanoma patients correlated with better overall survival [83]. Serum MMP8 levels did not correlate
with the presence of tumors in thyroid cancer patients [86]. High MMP8 expression, measured only
from circulating tumor cells, in the blood of metastatic castration-resistant prostate cancer patients
correlated with lower overall survival [88]. In lung cancer, measuring MMP8 levels in bronchial
washings had no value in terms of detection [89].
2.1.3. Genetics of MMP8 in Cancer
Cancer is a genetic disease in origin and various mutations, polymorphisms and DNA copy
number variances have been detected in different cancers. Studies on MMP8 genetics in cancer have
focused largely on single nucleotide polymorphisms (SNPs), which are collected in Table 3. Figure 2
illustrates the locations of studied SNPs in relation to the MMP8 gene.
Figure 2. Schematic illustration of MMP8 including the studied single nucleotide
polymorphisms (SNPs).
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Table 3. Matrix metalloproteinase 8 SNPs and prognosis.
Cancer SNPs Study Size (Patients + Healthy Controls) Effect on Patient (p-Value) Authors
Bladder rs11225395, rs35866072, rs34009635 375 + 375 No effect on bladder cancer risk. Tsai et al. 2018 [90]
rs11225395 200 + 200 Reduced risk of bladder cancer (p = 0.006). Srivastava et al. 2013 [91]
rs1940475 243 invasive, 315 superficial Protects from invasive phenotype in former smokers (p = 0.05). Kader et al. 2007 [92]
rs1940475 560 + 560 Trend to increased risk of invasive bladder cancer in never smokers (ns.). Kader et al. 2006 [93]
Breast rs11225395, rs35866072, rs34009635 1232 + 1232 No effect on breast cancer risk. Hsiao et al. 2018 [94]
rs11225395 6307 + 0 Better overall survival (p = 0.021). Beeghly-Fadiel et al. 2012 [95]
rs11225395 300 + 300 Not associated with breast cancer risk. De¸bniak et al. 2011 [96]
rs1940475, rs1320632, rs11225395,
rs17099436, rs10895353, rs7943404,
rs1892886, rs2508383, rs1276284
4470 + 4560 rs1892886: Associated with breast cancer (p = 0.0097). Mavaddat et al. 2009 [97]
rs10895353, rs7943404, rs11225395,
rs1320632, rs1940475, rs1892886,
rs17099436, rs2508383, rs1276284
1333 + 0
rs11225395, rs1940475, rs1892886 and rs1276284: Less metastasis
(p = 0.02, p = 0.03, p = 0.03, p = 0.03, respectively).rs11225395: Higher
overall (p = 0.02) and disease-specific survival (p = 0.02) and less relapse
(p = 0.04) in early stage patients.
Decock et al. 2007 [98]
Gastric rs1940475 254 + 0
Higher risk for recurrence (p = 0.005) and lower overall survival
(p = 0.001), recurrence-free survival (p = 0.005) and disease-free survival
(p = 0.011).
Lin et al. 2017 [36]
rs11225395, rs2155052 79 + 169 No correlation to risk or clinicopathological parameters. Kubben et al. 2006 [99]
Head and neck rs11225395, rs35866072, rs34009635 788 + 956 No effect on oral cancer risk. Hung et al. 2017 [100]
rs11225395 198 + 0 No significant effect on overall survival in NPC. Liu et al. 2013 [101]
rs11225395 136 + 0 No correlation to survival or LNM in HNSCC patients. Pradhan-Palikhe et al. 2010 [78]
Leukemia rs11225395, rs35866072, rs34009635 266 + 266 No effect on childhood leukemia risk. Pei et al. 2017 [102]
Liver rs11225395 434 + 480 Increased risk of HCC in non-HBV-carriers (p = 0.03). Qiu et al. 2008 [103]
Lung rs11225395, rs35866072, rs34009635 358 + 716 No effect on lung cancer risk. Shen et al. 2017 [104]
rs2155052 501 + 510
Reduced risk for lung cancer (p = 0.019), especially in males (p = 0.021),
ever smokers (p = 0.034) and patients with family history of lung cancer
(p = 0.011). Reduced risk for small cell carcinoma (p = 0.023) and
squamous cell carcinoma (p = 0.008).
González-Arriaga et al. 2008 [105]
Ovarian rs17099462 417 + 417 Reduced overall survival (p = 0.0257). Wang et al. 2015 [106]
rs11225395, rs2155052 35 malignant, 51 benign + 37 rs11225395: Increased risk for ovarian cancer (p = 0.02) and tendencytowards worse overall survival (ns.). Arechavaleta-Velasco et al. 2014 [107]
Skin rs1940475 285 SCC, 300 BCC, 218 melanoma + 870 Reduced risk for BCC (p = 0.04), no effect in SCC or melanoma. Nan et al. 2008 [108]
rs11225395 300 melanoma + 300 Increased risk for melanoma (p = 0.017). De¸bniak et al. 2011 [96]
Thyroid rs1940475 31 PTC, 19 FTC and 9 ATC + 0 Present in 80.6% of PTC, 73.6% of FTC and 88.8% of ATC tumors. Murugan et al. 2011 [109]
Abbreviations: ATC: Anaplastic thyroid carcinoma; BCC: Basal cell carcinoma; FTC: Follicular thyroid carcinoma; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma: HNSCC: Head
and neck squamous cell carcinoma; LNM: Lymph node metastasis; NPC: Nasopharyngeal cancer; ns.: not significant; PTC: Papillary thyroid carcinoma; SCC: Squamous cell carcinoma.
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2.1.3.1. The SNP rs1122539 Protects from Breast and Bladder Cancer but Increases the Risk of
Melanoma and Ovarian Cancer
The most studied SNP in the MMP8 gene is SNP rs11225395 (C-799T) located in the promoter
region that increases the transcription of MMP8 [98]. SNP rs11225395 is associated with a lower
risk of developing breast cancer and a higher overall survival from breast cancer as shown by three
independent studies [95,96,98]. Yet Hsiao et al. [94] found no correlation with breast cancer risk in
their population. Another study found that the same SNP correlated with reduced risk of bladder
cancer, even in smokers, but was not associated with tumor grade [91].
In contrast, SNP rs11225395 was associated with an increased risk of developing melanoma [96]
and ovarian cancer. Moreover, in ovarian cancer, a tendency towards worse overall survival was
found [107]. In the case of HNSCC, no correlation between SNP rs11225395 and survival of the patients
was found [78], nor was this SNP associated with risk of oral cancer [100]. Studies on the susceptibility
to hepatocellular carcinoma [103], bladder cancer [90], acute lymphatic leukemia in children [102] and
lung cancer [104] revealed no correlation to SNP rs11225395.
2.1.3.2. Fluctuating Findings on the Effect of SNP rs1940475
The SNP rs1940475 (A259G) is located in the pro-domain of MMP8 and alters the structural
stability of the domain, thus decreasing the activation of MMP8 [110]. Murugan et al. [109] revealed
that 73.6–88.8% of their thyroid carcinoma tumor samples harbored SNP rs1940475 and the authors
postulated, based on the location of this SNP, an effect on the function of MMP8. Later Lin et al. [36]
showed decreased enzymatic activity of MMP8 harboring this SNP as well as increased recurrence and
lower survival of gastric adenocarcinoma patients. Yet Kader et al. [92,93] found no correlation with
the risk of bladder cancer or its type to SNP rs1940475. Interestingly though, this SNP had a seemingly
protective effect in former smokers, but in never smokers there was a trend of increased risk of invasive
bladder cancer. Nan et al. [111] associated SNP rs1940475 with the risk of basal cell carcinoma (but
not SCC or melanoma) but the association was not significant in age-adjusted analysis. Based on the
studies, these cancers might benefit from having a MMP8-inactivating SNP suggesting that MMP8 is a
tumor-protective factor in them.
2.1.3.3. Other MMP8 SNPs Also Decrease Cancer Risks
Gonzalez-Arriaga et al. [105] found that SNP rs2155052 (C17G) in the MMP8 promoter region is
associated with decreased risk of lung cancer, especially in high-risk patients such as ever-smokers.
An intronic SNP rs1892886 is associated with breast cancer [97] and was also found to have a lower
frequency in patients with lymph node metastasis [98], along with SNPs rs11225395, rs1940475
and rs1276284. On the contrary to other studies, SNP rs17099462 decreased the expression of
MMP8 and was shown to be associated with the increased risk of death from ovarian cancer [106].
MMP8 SNPs rs35866072 and rs34009635 have no effect on the risks of childhood acute lymphocytic
leukemia [102], breast [94], bladder [90], oral [100] or lung cancer [104]. No MMP8 SNPs were correlated
to nasopharyngeal carcinoma [101] or gastric cancer and its clinicopathological features [99].
2.1.3.4. Studies on Somatic and Epigenetic Changes Strengthen the View of Active MMP8 as a
Tumor-Suppressive Factor
Only a few genetic studies on MMP8 other than SNP analyses have been reported.
Palavalli et al. [112] found that melanomas harbor somatic MMP8 mutations, which decrease MMP8
activity and lead to increased colony formation and cell migration in vitro as well as metastasis
formation in vivo. Accordingly, a microarray analysis of the epigenetic regulation of MMPs in breast
cancer and glioma cell lines revealed an epigenetic inactivation of MMP8 unlike other MMPs, which
could explain the reduction of active MMP8 in various malignancies unrelated to their genetics [113].
For miRNA studies, miR-539 was shown to directly target MMP8 3′-UTR along with other targets
thus inhibiting MMP8 expression. In osteosarcoma cells, the overexpression of this miRNA led to
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reduced proliferation, invasion and migration, suggesting MMP8 acts as a tumor-promoting factor in
osteosarcoma [114].
2.2. In Vitro Experimental Evidence and In Vivo Mouse Studies Elucidate the Molecular Mechanisms of MMP8
in Cancers
2.2.1. Studies in Skin Cancer Paved the Way for the Idea of Tumor-Suppressive MMP8
In vitro studies on skin cancer revealed that most melanoma cell lines, but not normal melanocytes,
express MMP8 mRNA [57]. Yet at the protein level, MMP8 was only present in half of the nine melanoma
cell lines examined by Giricz et al. [115]. Similarly, MMP8 mRNA expression in keratinocytes of
varying tumorigenic potential was detected in vitro but protein expression varied [116].
In vivo murine studies paint a clearer picture; male MMP8 knock-out (KO) mice were more
prone to carcinogen-induced skin and connective tissue cancers than the wild-type mice and the
protective effect of MMP8 could be restored by a bone marrow transplant from wild-type mice [117].
Subsequently, MMP8 KO mice were also shown to be susceptible to melanoma [27]. Murine melanoma
cells, B16F10, formed more lung metastases in MMP8 KO mice, whereas the overexpression of MMP8
in tumor cells lowered the number and size of metastases. MMP8 was also upregulated in the
secretome of DNA-dependent protein kinase, catalytic subunit (DNA-PKcs)-silenced melanoma cells
that metastasized less in vivo and migrated/invaded less in vitro [118], providing indirect evidence for
the protective role of MMP8. However, in B16F10-derived melanoma in C-C chemokine receptor 5 KO
mice, MMP8 had no effect on metastasis [119].
2.2.2. MMP8 Has Fluctuating Expression Profiles in Breast Cancer Cells In Vitro, but Rather Consistent
Tumor-Protective Effects In Vivo
Overall MMP levels increase during malignant transformation in breast cancer cell lines—so
does MMP8 as well [120]. Most studies [121–123], apart from Agarwal et al. [124], show that the
non-metastatic MCF-7 cell line produces no endogenous MMP8 protein. Yet, notoriously metastatic
MDA-MB-435, as well as less metastatic MDA-MB-468 [26,121] and MDA-MB-231 cells [122], do
produce MMP8. MMP8 mRNA expression is only detected in MDA-MB-231 cells [121,123,124], except
in one study that found no expression [125]. Co-culture with adipose tissue-derived mesenchymal
stem cells, a driver of tumorigenesis, did not affect the MMP8 expression of breast cancer cells [126].
Although MMP8 was mainly found to be expressed by metastatic cell lines and not the non-metastatic
MCF-7 cell line, many [123,124,127] have shown that MMP8-expressing breast cancer cell lines are
less invasive in vitro and generate less metastases in mice in vivo. Similar conclusions were drawn
by Decock et al. [128] and Soria-Valles et al. [129] in their studies on MMP8 KO mice. Systemic
MMP8 expression was found to decrease tumor size, hinder tumorigenesis and protect from metastasis
formation. Moreover, xenografted tumors in MMP8-deficient mice showed decreased vascularization
and neutrophil recruitment [128]. In their studies, MMP8 cleaved decorin, which inhibits TGF-β1:
The subsequent downregulation of miR-21 expression led to activation of known tumor suppressors
such as programmed cell death 4 (PDCD4) [129]. MMP8 has also been shown to affect the protease web
by, e.g., decreasing the levels of MMP3 [128] and MMP9 [62] in breast cancer cells, which was speculated
to decrease the malignant behavior of the cells [128]. Furthermore, MMP8 overexpression was shown
to increase the expression of interleukins 6 and 8 in breast cancer cells [123], which was postulated
to be connected to inflammatory response rather than cancer progression. Accordingly, MMP8
overexpressing breast cancer cells had reduced migratory and proliferative properties in vitro [129].
Similarly, MMP8 overexpressing breast myoepithelial cells show increased adhesion, due to retraction
fiber shortening and differential localization of integrin α6β4 [62]. The variable results might be
explained by heterogeneity between cell lines, sensitivity differences between methods, or as shown by
Bachmeier et al. [121]; confluence of the cell culture. However, MMP8 was shown not to be involved
in the tumor-promoting effects of TLR9 and relaxin that induced the activity of many MMPs in
breast cancer cells thereby increasing cell invasiveness [130,131]. In contrast, tumor-induced systemic
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inflammation in breast cancer increased metastasis generation in mice due to neutrophil-mediated
tumor cell extravasation and inhibition of tumor cell clearance. Additionally, these neutrophils were
shown to secrete increased amounts of MMP8 and MMP9, which facilitated tumor cell extravasation
and metastasis [132]. Thus, MMP8 expression, although low in non-malignant breast cancer cells,
seems to act as a tumor suppressor rather than an enhancer in malignant cells but not in neutrophils.
It is important to note that factors elevated during cancer progression should not be interpreted as
tumor promoters.
2.2.3. Tumor-Protective Molecular Mechanisms of MMP8
Several studies show that MMP8 triggers tumor-suppressive molecular cascades after cleavage of
various non-ECM substrates, as shown in Figure 3. Indeed, it has also been shown that collagenolytic
activity did not decrease in fibroblasts isolated from MMP8 KO mice [133], suggesting other MMPs
than MMP8 were the source of collagenolysis in vivo. However, Korpi et al. [44] found that female
MMP8 KO mice are especially prone to carcinogen-induced tongue cancer and that MMP8 cleaves
estrogen receptors α and β. Later, MMP8 overexpression was shown to reduce the invasion and
migration of OTSCC cells in vitro and to change the gene and protein expression of various factors,
including a decrease in VEGF-C [39]. Lung adenocarcinoma cells treated with hepatocyte growth
factor variants showed inhibition of proliferation, reduced invasion and increased amounts of active
MMP8, which was suggested to facilitate the tumor-protective effects [134]. On the other hand, MMP8
mRNA expression increased along other MMPs in aggressive lung cancer cell lines resistant to targeted
chemotherapy [135]. Additionally, Pellinen et al. [136] showed that silencing of MMP8 in prostate
cancer cells led to increased ligand binding of β1 integrin and higher prostate cancer cell invasion
in vitro as well as increased breast cancer lung extravasation in vivo. Yet overexpression of integrin
α6β4 in OSCC cells did not change MMP8 mRNA expression, which shows, that MMP8 affects integrin
but not vice versa [137].
Figure 3. Suggested molecular mechanisms of MMP8. Abbreviations: Akt: RAC-α
serine/threonine-protein kinase; Arf1: ADP-ribosylation factor 1; ECM: Extracellular matrix; EphB2:
Ephrin type B receptor 2; ER-α/β: Estrogen receptor α/β; IL-6/8: Interleukin 6/8; MMP3: Matrix
metalloproteinase 3; MMP8: Matrix metalloproteinase 8; PDCD4: Programmed cell death 4; PI3K:
Phosphoinositide 3-kinase; TGF-βR: Transforming growth factor β receptor: TGF-β1: Transforming
growth factor β-1. See references (in superscript) for original publications.
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2.2.4. Tumor-Promoting Molecular Mechanisms of MMP8
MMP8 exhibits some pro-tumorigenic effects through substrate cleavage: Ephrin-B1 belongs to
an ephrin family of proteins, which transduce signals related to cell adhesion and angiogenesis [138].
The intracellular C-terminus of ephrin-B1, that is required for invasion of pancreatic cancer cells in vitro
and in vivo in mice, was shown to regulate the release of MMP8 from these cells via activation of the
cell trafficking regulator, Arf1 [139]. Furthermore, the released MMP8 could cleave the ectodomain of
ephrin-B1, in a potential feedback mechanism to downregulate the activity of ephrin-B1. Later it was
shown that a peptide from the ephrin-B1 C-terminus can block the release of MMP8 and can inhibit
the invasion of gastric scirrhous carcinoma cells in vitro and their peritoneal dissemination in vivo
in mice [140]. Although MMP8 in vitro was shown to cleave laminin5 γ2-chains (a basal membrane
component known to induce migration when cleaved), its addition to MCF-7 breast cancer cells had
no impact on their migration over laminin [141].
Other pro-tumorigenic effects of MMP8 may be linked to signaling properties of MMP8: MMP8
itself upregulates TGF-β1 expression by activating the PI3K/Akt/Rac1-pathway, which in turn leads
to an epithelial-mesenchymal transition (EMT), and subsequently, increased invasion and migration
of hepatocellular carcinoma cells [48]. Bone marrow cells produce MMP8 along with other MMPs
during multiple myeloma progression in vivo and the tumor growth can be reduced with the broad
spectrum MMP inhibitor; SC-964 [142]. Various factors known to promote tumorigenesis were shown
to increase MMP8 expression or activity in vitro: CD44- and CD24-expressing renal cell carcinoma stem
cell subsets, serpinA1-expressing gastric cancer cells and CCL25-expressing ovarian cancer cells all
showed higher migratory and invasive potential in vitro as well as higher MMP8 expression [143–145].
Interestingly, in prostate cancer cells, no MMP8 was detected even after induction with CCL25 [146].
In vitro in OSCC cells, betel quid increased MMP8 levels and cell migration [147], whereas trypsin-2
activated MMP8 [148]. Yet, endostatin, anti-angiogenic collagen XVIII fragment had no inhibitory
effect on MMP8 although it could inhibit migration [149]. However, none of these studies examined
how changes in the level of MMP8 affected the cancer cells.
2.2.5. MMP8 Expression Is Not Detected at All in Some Cancer Cell Lines
In some cancer cell lines, no MMP8 mRNA was detected, such as in bladder cancer [150],
Ewing’s sarcoma [151], chondrosarcoma [152] or follicular thyroid carcinoma cells [153], and thus,
the mechanistic role of MMP8 in those cancers has not been examined. Additionally, no MMP8 gene
expression was found in stellate cells—building blocks of the ECM in pancreatic cancer [154]. In renal
cell carcinoma, no differences in MMP8 gene expression were detected between healthy and cancerous
kidney tissue as well as bone metastasis [155]. MMP8 expression is detected in fibrosarcoma cell
lines, but not in the in vivo chorioallantoic membrane (CAM) assay, which is used to study tumor
angiogenesis and invasion [156].
2.3. The Potential of MMP8 in Cancer Treatment
2.3.1. Using MMP8 as a Pharmaceutical Adjuvant Shows Promising Results
Three independent studies show that MMP8 reduces interstitial tumor fluid pressure, increases
fluid flow in various murine tumors, namely lung cancer, soft tissue sarcoma and HNSCC, and
enhances the efficacies of oncolytic virus therapy and liposomal drugs [157–159]. Thus, MMP8 could be
a potential adjuvant drug. Additionally, variating levels of MMPs, MMP8 included, can be visualized
with tomography methods in breast cancer tumors in vivo (murine), offering a diagnostic tool to
evaluate tumor progression and heterogeneity [160].
2.3.2. Cancer Treatments Affect MMP8 Levels in Tumors
Many cancer drugs can decrease MMP8 levels along with other MMPs: The plant-based isoflavones
genistein and glycitein, as well as the flavone apigenin, down-regulate MMP8 expression in vitro and
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inhibit leukemia cell invasion [161,162] and decrease the viability of hepatocellular carcinoma cells [163].
Saponins from the plant Rhizoma paridis decreased the expression of inflammatory cytokines and
MMP8 as well as reduced lung cancer tumor volume and growth in mice [164]. Therapeutic gold
nanoparticles, which decreased ovarian cancer tumor growth and metastasis in vivo, also inhibited
ovarian cancer cell proliferation, decreased MMP8 expression, and altered cytokine production
in vitro [165]. Treatment with the cytotoxic peptide HNP-1 reduced the levels of MMP8 as well as
increased lactate dehydrogenase toxicity in OSCC cell lines but did not affect cell viability [166].
Reduced levels of MMP8 were observed when glioblastoma multiforme spheroids were treated with
5-aminolevulinic acid-photodynamic therapy [167]. MMP8 levels in blood decreased after tumor
removal in paraganglioma [168] and pancreatic ductal adenocarcinoma patients [85]. Systemic changes
in MMP8 levels after cancer treatment might be explained by the changes in systemic inflammation.
On the other hand, several studies show that some cancer treatments may also increase MMP8
levels: Increased expression of proangiogenic factors, including MMP8, by myeloid derived suppressor
cells could contribute to resistance to Sunitinib treatment seen in some kidney cancer patients [169].
Treatment of bladder cancer with bacterial CBM588 strongly inhibited the tumor growth in vivo in
mice, which was suggested to be due to the release of TNF-related apoptosis-inducing ligand (TRAIL)
from PMN cells by MMP8 [170]. An in vitro prostate cancer study by Reel et al. [171] showed that
Zoledronate, an inhibitor of osteoclastic bone resorption, downregulates discoidin domain receptor
proteins—known MMP activators. Subsequently, the MMP levels were downregulated except for
MMP8, which increased. The progesterone receptor modulator CDB-2914, induces MMP expression,
including MMP8, in uterine leiomyoma cells, but MMP8 is not activated by this treatment and its role
remains unclear [172]. In skin cancer, immunosuppression does not change MMP8 expression levels or
its location [173], nor did MMP8 expression in skin SCC tumors correlate with its aggressiveness in
immunosuppressed transplant patients [64].
2.3.3. High MMP8 Levels Can Guide Treatment Choices and Indicate Harmful Post-Operative
Reactions in Some Patients
High serum MMP8 levels could be used to define cutaneous melanoma patients who would
benefit from interferon-α (IFN-α) therapy [174]. Yet Van Roy et al. [175] showed earlier that MMP8
deficiency does not change the survival of mice inoculated with B16BL6 melanoma tumor cells and
treated with TNF/IFNγ therapy. Lin et al. [176] showed that prostate cancer patients with MMP8 SNP
rs11225395 benefit more from androgen deprivation therapy than other patients.
MMP8 levels in some body fluids can also be used to assess post-operative reactions: HNSCC
patients, who developed radiochemotherapy-induced oral mucositis, had a higher salivary MMP8
level than those who did not develop this reaction [177]. Elevated MMP8 levels in intraperitoneal fluid
were also seen in rectal cancer patients who developed anastomotic leakage after surgery [178].
2.3.4. MMP8 as an Anti-Target for MMP Inhibitors
Inhibition of MMPs has been considered as a potential clinical intervention in cancer treatment.
The first synthetic MMP inhibitors (MMPIs); Batimastat (BB-94) and Marimastat (BB-2516), were
developed almost 20 years ago and they showed promising results in murine studies, e.g., by reducing
the tumor volume in ovarian cancer [179]. They were rushed to clinical trials and disappointment
ensued—no effects on tumors were seen, yet the side effects for patients, such as pain in bones, were
significant [180]. Recently, the development of MMPIs has moved away from general MMPIs [181–
183] towards specific inhibitors for MMP1 [184], gelatinases [185–187], MMP11 [188] and specific
cancers [189] or stages of tumor progression [190]. However, specificity is an issue due to the high level
of sequence and structural homology between MMPs, and some of these “specific” inhibitors also bind
MMP8. Previously, inhibitors were designed specifically for MMP8 [191]. Since the tumor-protective
effects were demonstrated in 2003, MMP8 has been regarded as an anti-target in MMP inhibitor
development [192–194]. However, MMP8 expression has also been shown to increase in highly
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vascularized tissues such as tumor and placenta [195] and this protease is generally regarded as
a proangiogenic factor. Angiogenesis is a major target in cancer treatment and MMPIs have been
developed against proangiogenic MMPs such as MMP8 and MMP9 [108,196].
3. Discussion
In this systematic review we gathered the available data from the Scopus database on the role of
MMP8 in cancer, including the use of MMP8 as a biomarker for prognosis in tumors, blood, and at
the genetic level, in vivo and in vitro studies on its molecular mechanisms as well as its use in cancer
therapy. The limitation of the study is the use of one database only. In addition, given the large number
of studies included an in-depth analysis of individual studies was prevented. Meta-analyses were not
performed due to the high variability between different studies as well as the poor number of studies
per cancer type.
In general, MMP8 levels in tumors variate and are not always detected. The studies published to
date, suggest that high MMP8 protein levels might predict better survival for tongue [39,44] and some
breast [27] cancer patients, but they provide a worse prognosis in hepatocellular [48] and ovarian [50,51]
cancers. Results variate greatly for some, such as colorectal cancer [31–34]. However, mRNA levels are
even more inconsistent. This phenomenon can partly be explained by different sources of MMP8 in the
body, such as tumor cells and neutrophils. Not all studies state where the analyzed MMP8 staining is
localized (tumor cells, neutrophils, tumor stroma, etc.), which might partly explain the inconsistency.
The presence of cancer seems to increase the level of MMP8 in circulation and depending on the
cancer, high plasma MMP8 levels might be beneficial (e.g., breast cancer [73]), but in some cancers
(colorectal [32,74,75], hepatocellular [82] and melanoma [83]) high serum MMP8 levels correlate with
poor prognosis. Additionally, it should be noted that serum and plasma may give contradicting results;
plasma contains blood cells including neutrophils, which might release additional MMP8 in the sample
after collection. SNPs, which modulate MMP8 transcription and activity, seem to play the strongest
role in cancer prognosis and are beneficial for breast [95,98], bladder [91,93] and gastric [36] cancer
patients but detrimental in ovarian [107] cancer patients. Other SNPs and genetic modifications have
been poorly studied or do not correlate with clinicopathological parameters.
In vitro experiments and in vivo murine studies shed light on the non-collagenolytic actions
of MMP8 and strengthen the findings from in vivo patient data. These studies were the first to
introduce the idea of tumor-protective MMP8 in skin cancer [27,117] and breast cancer [124,127–129].
In these cancers, MMP8 slows the metastatic process both in vivo and in vitro, which explains why
patients benefit from MMP8. Studies have also revealed non-collagen substrates for MMP8 including
transmembrane proteins, cytokines and signaling molecules. However, MMP8 activity can also be
harmful, as shown for pancreatic and gastric cancers [138,140], in which the interaction between MMP8
and Ephrin-B1 seems crucial, and hepatocellular carcinoma [48], where MMP8 was shown to activate
the PI3K/Akt/Rac1 pathway.
MMP8 is nowadays considered an anti-target in cancer drug development. However, many cancer
therapies modulate MMP8 levels—this might present changes in systemic inflammation. The use
of MMP8 in treatment selection and for the evaluation of harmful post-operative reactions has not
been fully examined in various cancers but it might be useful in those cancers where MMP8 has been
shown to play a role. The use of MMP8 as an adjuvant [157–159] in cancer drug treatment poses
unappreciated potential and should be further studied.
The role of MMP8 seems more definite in those cancers, that are well studied—e.g., the effects of
MMP8 in breast cancer is studied in more than 30 research articles. When the tumor-protective role
of MMP8—a novel function for proteases at that time, was first reported in 2003 in breast and skin
cancers, it probably increased the interest in the role of MMP8 specifically in those cancers. However,
to evaluate the overall function of MMP8 in various steps of cancer progression, the tumor-promoting
mechanisms of this multifunctional enzyme should also be studied.
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4. Materials and Methods
This article was compiled by following the systematic review guide—Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) [197]. The workflow is depicted in Figure 4.
Searches were run using the Scopus (https://www.scopus.com) database with the assistance of an
information specialist. The search terms MMP8 (mmp 8 OR matrix metalloproteinase 8 OR neutrophil
collagenase OR collagenase 2) and cancer (cancer OR neoplasm* OR carcinoma* OR malignan* OR
tumo?r* OR sarcoma* OR leukemi* OR lymphoma* OR adenocarcinoma*) were searched from titles,
abstracts and keywords, where the asterisk (*) is used to indicate truncation and the question mark (?)
is used to indicate wildcard characters.
Figure 4. Workflow for literature search.
A total of 692 hits were retrieved. Next, articles written in languages other than English, published
before 1st January, 1990 and after 1st January, 2019 or which were not original research articles were
excluded. After the first exclusion, the abstracts of the remaining 431 articles were carefully analyzed.
After an abstract review, articles were excluded if they were a review, or if MMP8 was not studied,
or if the study did not focus on cancer—leading to 168 collected articles. The articles excluded by
Scopus (217) were manually checked and three articles were returned. Thus, a total of 171 articles were
included in this systematic review. To answer our specific research questions (“can MMP8 be used as a
prognostic factor in cancer?”; “what are the molecular mechanisms of MMP8 in cancer?”; and “can
MMP8 be used in cancer treatment?”) the information about study size and type, methodology, patient
outcome, main findings and statistical results were retrieved.
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Abbreviations
DFS Disease-free survival
ECM Extracellular matrix
EMT Epithelial-mesenchymal transition
HNSCC Head and neck squamous cell carcinoma
MMP Matrix metalloproteinase
MMP8 Matrix metalloproteinase 8
MMPI Matrix metalloproteinase inhibitor
OS Overall survival
OSCC Oral squamous cell carcinoma
OTSCC Oral tongue squamous cell carcinoma
PMN Polymorphonuclear neutrophils
RFS Recurrence- or relapse-free survival
SCC Squamous cell carcinoma
SNP Single nucleotide polymorphism
TGF-β1 Transforming growth factor β1
TIMP-1 Metalloproteinase inhibitor 1
VEGF-C Vascular endothelial growth factor C
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